BioCorRx (BICX) Osake Kurssi

BioCorRx Inc is primarily active in the healthcare and pharmaceutical industries.

The main competitors of BioCorRx Inc in the market include pharmaceutical companies, such as Pfizer Inc, Johnson & Johnson, and Novartis AG. Other competitors in the addiction treatment industry include Alkermes plc and Indivior Inc. These companies operate in the same market, offering various products and services for addiction treatment. BioCorRx Inc, a leader in medication-assisted treatment solutions, competes with these companies through its innovative treatment program, BioCorRx Recovery.

BioCorRx Inc is a pharmaceutical company specializing in innovative addiction treatment solutions. Established in 2008, BioCorRx is dedicated to developing effective medications and programs to support those struggling with alcohol and opioid dependencies. The company focuses on combining its proprietary medication, known as the BioCorRx® Recovery Program, with cognitive-behavioral therapy to enhance patient outcomes and reduce relapse rates. With a mission to improve the lives of individuals battling addiction, BioCorRx Inc strives to provide comprehensive and personalized treatment options. Through its commitment and innovative approach, BioCorRx Inc has positioned itself as a leading player in the addiction treatment industry.

BioCorRx Inc, a leading pharmaceutical company, has accomplished several significant milestones in recent years. One of their key achievements includes the development and commercialization of their flagship product, the BioCorRx Recovery Program, which offers a unique, non-addictive approach to treating substance abuse. The company has also made remarkable strides in expanding their distribution networks, forging partnerships with healthcare professionals, and achieving regulatory approvals for their innovative products. Moreover, BioCorRx Inc has consistently demonstrated a commitment to research and development, continually exploring new avenues for improving addiction treatment. These accomplishments highlight BioCorRx Inc's dedication to revolutionizing the field of substance abuse recovery.

BioCorRx Inc is primarily present in the United States. Recognized as a leader in substance use disorder treatment, BioCorRx operates its headquarters in Anaheim, California. With a focus on developing innovative solutions for addiction recovery, the company's presence spans the entire US territory. BioCorRx Inc is dedicated to helping individuals overcome addiction and promoting healthier lives.

BioCorRx Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions in the field of substance use disorder treatment. BioCorRx focuses on developing safe and effective approaches to help individuals overcome addiction and reclaim their lives. With a patient-centric approach, the company aims to provide comprehensive programs that combine medication-assisted treatment with behavioral support. BioCorRx exemplifies integrity, compassion, and a commitment to improving the well-being of individuals struggling with addiction. Through their cutting-edge solutions, BioCorRx Inc strives to make a positive impact in the field of addiction treatment and contribute to the overall betterment of society.

Nykyisellä valuuttakurssilla BioCorRx-osake noteerataan hintaan 0,18 EUR (0,20 USD).

BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in the development and sale of medications for the treatment of drug and alcohol addiction. The company has two different divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on the research, development, and marketing of naltrexone micro-implants for use in alcohol and opioid addiction. These micro-implants are small, biocompatible pellets that are implanted under the skin to allow for continuous release of naltrexone, reducing withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license for the development of buprenorphine implants for the treatment of opioid addiction. The second division, BioCorRx Health, offers a unique integrative health solution for the treatment of addiction disorders. This program includes a variety of services, including program guidance, phone support, online courses, nutritional counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach that is truly personalized to the patient and their needs. In addition, BioCorRx Inc offers a range of additional products that help reduce addictive behavior and enhance the success of the program. These include capsules for support during withdrawal, special supplements for patients with N-acetylcysteine deficiency, and enhanced vitamin and mineral supplements. BioCorRx Inc has established a strong presence in the US market and is expanding its global presence. The company has formed strategic partnerships with distribution partners to market its products and services worldwide. BioCorRx has also built excellent relationships with addiction researchers, medical professionals, and leading addiction treatment centers. The business model of BioCorRx Inc is based on two pillars: the marketing of patented medications for the treatment of addiction disorders and the sale of integrative health solutions. The company aims to offer a complete, integrated program for the treatment of addiction disorders, which includes both pharmacological treatments and supportive services. Due to the high demand for effective addiction treatments and the high demand for innovative solutions, BioCorRx Inc's business is promising. The company is well positioned to continue growing and dominate the addiction treatment market. The translation is as follows: BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in developing and selling medications to treat drug and alcohol addiction. The company has two divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on researching, developing, and marketing naltrexone micro-implants for alcohol and opioid addiction. These micro-implants are small, biocompatible pellets implanted under the skin to release naltrexone continuously and reduce withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license to develop buprenorphine implants for opioid addiction. BioCorRx Health offers a unique integrative health solution for addiction treatment, including program guidance, phone support, online courses, nutrition counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach tailored to each patient's needs. Additionally, BioCorRx Inc provides products to reduce addictive behavior and enhance program success. These include withdrawal support capsules, special supplements for N-acetylcysteine deficiency, and improved vitamin and mineral supplements. With a strong presence in the US market and plans for global expansion, BioCorRx Inc has formed strategic partnerships to market its products and services worldwide. The company has also established relationships with addiction researchers, medical professionals, and leading addiction treatment centers. BioCorRx Inc's business model focuses on marketing patented addiction medications and selling integrative health solutions. The company strives to offer a comprehensive program that combines pharmaceutical treatments with supportive services. Given the high demand for effective addiction treatments and innovative solutions, BioCorRx Inc is well positioned for growth and market dominance in addiction treatment.

odotettu liikevaihto BioCorRx on 971 850,00 USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto BioCorRx on −2,20 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

BioCorRx:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,24. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BioCorRx-osakkeen arvostusta.

BioCorRx:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,06. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BioCorRx-osakkeen arvostuskennuslukuna.

BioCorRx:n Eulpool-laatuscore on 7/10.

BioCorRx:n ISIN on US09073C2052. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

BioCorRx:n WKN on A1XERB. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

BioCorRx:n ticker on BICX. Tämä pörssinoteeraus käytetään BioCorRx-osakkeiden kauppaan pörssissä.